A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

NCT00441103 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Rebif® New Formulation (IFN-beta-1a, RNF)
DRUG: Placebo
DRUG: Rebif® New Formulation (IFN-beta-1a, RNF)

Sponsor

Merck KGaA, Darmstadt, Germany